Erratum to: Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B: HEPATOLOGY, Vol. XX, No. X, 2015 (Hepatology, (2016), 63, 2, (377-387), 10.1002/hep.28015);Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B

Hepatology

Volumn 63, Issue 2, 2016, Pages 377-387

  Jonas, Maureen M ^a   Chang, Mei Hwei ^b   Sokal, Etienne ^c   Schwarz, Kathleen B ^d   Kelly, Deirdre ^e   Kim, Kyung Mo ^f   Ling, Simon C ^g   Rosenthal, Philip ^h   Oraseanu, Dumitru ⁱ   Reynolds, Laurie ^j   Thiry, Alexandra ^j   Ackerman, Peter ^j  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d JOHNS HOPKINS CHILDREN S CENTER   (United States)

^e BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^f University of Ulsan College of Medicine   (South Korea)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Clinic of Plastic Surgery Reconstructive Microsurgery and Burns   (Romania)

^j BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; PLACEBO; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ANTIVIRAL RESISTANCE; ARTICLE; CHILD; CHRONIC HEPATITIS B; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FEVER; HEADACHE; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SEROCONVERSION; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; HEPATITIS B, CHRONIC; MULTICENTER STUDY; VIROLOGY;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE;

EID: 84956665697     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29011     Document Type: Erratum

References (39)

1. Paganelli M, Stephenne X, Sokal EM. Chronic hepatitis B in children and adolescents. J Hepatol 2012;57:885-896.
2. Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol 2013;59:814-829.
3. Anonymous. Viread (tenofovir) European Summary of Product Characteristics. Cambridge, UK: Gilead Sciences International Limited; April 2011.
4. ® A (Interferon alfa-2b). US product information; Whitehouse Station, NJ: Schering Corporation; 2014.
5. Anonymous. Epivir (lamivudine). US prescribing information. Middlesex, UK: ViiV Healthcare; November 2011.
6. Anonymous. Viread (tenofovir). US prescribing information. Foster City, CA: Gilead Biosciences; August 2012.
7. Anonymous. Hepsera (adefovir dipivoxil). US prescribing Information. Cambridge, UK: Gilead Sciences International Limited; 2012.
8. Anonymous. Tyzeka (telbivudine), US prescibing information. Basel, Switzerland: Novartis; December 2011.
9. Comanor L, Minor J, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, et al. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. J Viral Hepat 2001;8:139-147.
10. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-1303.
11. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495.
12. Jonas MM, Kelly D, Pollack H, Mizerski J, Sorbel J, Frederick D, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008;47:1863-1871.
13. Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012;35:1317-1325.
14. Tien C, Xu JJ, Chan LS, Chang M, Lim C, Lee S, et al. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. Dig Dis Sci 2015;60:566-572.
15. Gracey DM, Snelling P, McKenzie P, Strasser SI. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther 2013;18:945-948.
16. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008;152:582-584.
17. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
18. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
19. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int 2012;6:531-561.
20. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
21. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
22. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-79.
23. Chang TT, Lai CL, Kew YS, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-430.
24. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
25. Chang M, Kelly D, Kerkar N, Jonas M, Rosenthal P, Ackerman P, et al. Entecavir pharmacokinetics among nucleos/tide-naïve pediatric subjects. Hepatology 2013;58:685A.
26. Schwimmer JB, Dunn W, Norman GJ, Pardee PE, Middleton MS, Kerkar N, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010;138:1357-1364, 1364.e1-2.
27. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012;143:619-628.e1.
28. Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20.
29. Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008;48:895-902.
30. Oommen PT, Wirth S, Wintermeyer P, Gerner P. Relationship between viral load and genotypes of hepatitis B virus in children with chronic hepatitis B. J Pediatr Gastroenterol Nutr 2006;43:342-347.
31. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
32. Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-1713.
33. Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-232.
34. Murray KF, Szenborn L, Wysocki J, Rossi S, Corsa AC, Dinh P, et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012;56:2018-2026.
35. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
36. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
37. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797-1803.
38. Anonymous. Baraclude (entecavir). US prescribing information. New York: Bristol-Myers Squibb; December 2010.
39. Anonymous. Baraclude-EU package leaflet. Anagni, Italy: Bristol-Meyers Squibb Srl; 2014.